{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:18:46Z","timestamp":1787728726397,"version":"build-2784847793"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1208\/s12248-020-00446-z","type":"journal-article","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T05:04:43Z","timestamp":1585890283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Subcutaneous Site-of-Absorption Study with the Monoclonal Antibody Tocilizumab in Minipigs: Administration Behind Ear Translates Best to Humans"],"prefix":"10.1208","volume":"22","author":[{"given":"Wolfgang F.","family":"Richter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Gouy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susi","family":"S\u00f8gaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Kreuzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Wessels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragomir","family":"Draganov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Muenzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonio","family":"Hoche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,3]]},"reference":[{"issue":"286","key":"446_CR1","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jconrel.2018.08.001","volume":"2","author":"M Viola","year":"2018","unstructured":"Viola M, Sequeira J, Sei\u00e7a R, Veiga F, Serra J, Santos AC, et al. Subcutaneous delivery of monoclonal antibodies: how do we get there? J Control Release. 2018;2(286):301\u201314. https:\/\/doi.org\/10.1016\/j.jconrel.2018.08.001.","journal-title":"J Control Release"},{"issue":"5","key":"446_CR2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","volume":"32","author":"B Bittner","year":"2018","unstructured":"Bittner B, Richter W, Schmidt J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs. 2018;32(5):425\u201340. https:\/\/doi.org\/10.1007\/s40259-018-0295-0.","journal-title":"BioDrugs."},{"issue":"4","key":"446_CR3","first-page":"461","volume":"12","author":"TA McDonald","year":"2010","unstructured":"McDonald TA, Zepeda ML, Tomlinson MJ, Bee WH, Ivens IA. Subcutaneous administration of biotherapeutics: current experience in animal models. Curr Opin Mol Ther. 2010;12(4):461\u201370.","journal-title":"Curr Opin Mol Ther"},{"key":"446_CR4","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1208\/s12248-012-9367-0","volume":"14","author":"WF Richter","year":"2012","unstructured":"Richter WF, Bhansali SG, Morris ME. Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J. 2012;14:559\u201370.","journal-title":"AAPS J"},{"issue":"2","key":"446_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.4161\/mabs.4.2.19387","volume":"4","author":"Y Zheng","year":"2012","unstructured":"Zheng Y, Tesar DB, Benincosa L, Birnb\u00f6ck H, Boswell CA, Bumbaca D, et al. Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration. MAbs. 2012;4(2):243\u201355. https:\/\/doi.org\/10.4161\/mabs.4.2.19387.","journal-title":"MAbs"},{"issue":"11","key":"446_CR6","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1124\/dmd.114.059238","volume":"42","author":"WF Richter","year":"2014","unstructured":"Richter WF, Jacobsen B. Subcutaneous absorption of biotherapeutics: knowns and unknowns. Drug Metab Dispos. 2014;42(11):1881\u20139. https:\/\/doi.org\/10.1124\/dmd.114.059238.","journal-title":"Drug Metab Dispos"},{"key":"446_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.7326\/0003-4819-92-1-59","volume":"92","author":"VA Koivisto","year":"1980","unstructured":"Koivisto VA, Felig P. Alterations in insulin absorption and in blood glucose control associated with varying insulin injection sites in diabetic patients. Ann Intern Med. 1980;92:59\u201361.","journal-title":"Ann Intern Med"},{"issue":"5","key":"446_CR8","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1365-2265.1991.tb03557.x","volume":"35","author":"SA Beshyah","year":"1991","unstructured":"Beshyah SA, Anyaoku V, Niththyananthan R, Sharp P, Johnston DG. The effect of subcutaneous injection site on absorption of human growth hormone: abdomen versus thigh. Clin Endocrinol. 1991;35(5):409\u201312.","journal-title":"Clin Endocrinol"},{"issue":"3","key":"446_CR9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/j.1365-2265.1994.tb03934.x","volume":"40","author":"T Laursen","year":"1994","unstructured":"Laursen T, J\u00f8rgensen JO, Christiansen JS. Pharmacokinetics and metabolic effects of growth hormone injected subcutaneously in growth hormone deficient patients: thigh versus abdomen. Clin Endocrinol. 1994;40(3):373\u20138.","journal-title":"Clin Endocrinol"},{"issue":"3","key":"446_CR10","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1177\/0091270009340782","volume":"50","author":"Z Xu","year":"2010","unstructured":"Xu Z, Wang Q, Zhuang Y, Frederick B, Yan H, Bouman-Thio E, et al. Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects. J Clin Pharmacol. 2010;50(3):276\u201384. https:\/\/doi.org\/10.1177\/0091270009340782.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"446_CR11","doi-asserted-by":"publisher","first-page":"e12278","DOI":"10.1111\/1755-5922.12278","volume":"35","author":"Ellen Q. Wang","year":"2017","unstructured":"Wang EQ, Plotka A, Salageanu J, Sattler C, Yunis C. Pharmacokinetics and pharmacodynamics of bococizumab, a monoclonal antibody to PCSK9, after single subcutaneous injection at three sites [NCT 02043301]. Cardiovasc Ther. 2017;35(5). https:\/\/doi.org\/10.1111\/1755-5922.12278.","journal-title":"Cardiovascular Therapeutics"},{"issue":"6","key":"446_CR12","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/cpdd.617","volume":"8","author":"N Kotani","year":"2019","unstructured":"Kotani N, Yoneyama K, Kawakami N, Shimuta T, Fukase H, Kawanishi T. Relative and absolute bioavailability study of emicizumab to bridge drug products and subcutaneous injection sites in healthy volunteers. Clin Pharmacol Drug Dev. 2019;8(6):702\u201312. https:\/\/doi.org\/10.1002\/cpdd.617.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"446_CR13","unstructured":"Actemra package insert. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125276s092lbl.pdf. Accessed September 15, 2019."},{"issue":"11","key":"446_CR14","doi-asserted-by":"publisher","first-page":"803","DOI":"10.4155\/bio-2018-0047","volume":"10","author":"U Wessels","year":"2018","unstructured":"Wessels U, Zadak M, Reiser A, Brockhaus J, Ritter M, Abdolzade-Bavil A, et al. Immunogenicity testing of therapeutic antibodies in ocular fluids after intravitreal injection. Bioanalysis. 2018;10(11):803\u201314. https:\/\/doi.org\/10.4155\/bio-2018-0047.","journal-title":"Bioanalysis."},{"issue":"2","key":"446_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2165\/11537430-000000000-00000","volume":"50","author":"JQ Dong","year":"2011","unstructured":"Dong JQ, Salinger DH, Endres CJ, Gibbs JP, Hsu CP, Stouch BJ, et al. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet. 2011;50(2):131\u201342. https:\/\/doi.org\/10.2165\/11537430-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"446_CR16","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","volume":"49","author":"NL Dirks","year":"2010","unstructured":"Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(10):633\u201359. https:\/\/doi.org\/10.2165\/11535960-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"key":"446_CR17","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1124\/dmd.114.059121","volume":"42","author":"L Kagan","year":"2014","unstructured":"Kagan L. Pharmacokinetic modeling of the subcutaneous absorption of therapeutic proteins. Drug Metab Disp. 2014;42:1890\u20131905.18.","journal-title":"Drug Metab Disp"},{"issue":"4","key":"446_CR18","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/jcph.826","volume":"57","author":"H Abdallah","year":"2017","unstructured":"Abdallah H, Hsu JC, Lu P, Fettner S, Zhang X, Douglass W, et al. Pharmacokinetic and pharmacodynamic analysis of subcutaneous tocilizumab in patients with rheumatoid arthritis from 2 randomized, controlled trials: SUMMACTA and BREVACTA. J Clin Pharmacol. 2017;57(4):459\u201368. https:\/\/doi.org\/10.1002\/jcph.826.","journal-title":"J Clin Pharmacol"},{"key":"446_CR19","unstructured":"European Medicines Agency, Assessment report RoActemra, EMA\/CHMP\/606295\/2013, 20 February 2014. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/roactemra-h-c-955-x-0030-epar-assessment-report-variation_en.pdf. Accessed January 17, 2020."},{"key":"446_CR20","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s11095-013-1154-9","volume":"31","author":"V Filipe","year":"2014","unstructured":"Filipe V, Que I, Carpenter JF, L\u00f6wik C, Jiskoot W. In vivo fluorescence imaging of IgG1 aggregates after subcutaneous and intravenous injection in mice. Pharm Res. 2014;31:216\u201327. https:\/\/doi.org\/10.1007\/s11095-013-1154-9.","journal-title":"Pharm Res"},{"issue":"6","key":"446_CR21","first-page":"9","volume":"30","author":"DW Kang","year":"2013","unstructured":"Kang DW, Nekoroski TA, Printz MA, Hoh CK, Vera DR, Skipper JF, et al. Recombinant human hyaluronidase PH20 (rHuPH20) facilitated subcutaneous delivery of proteins in nonclinical models. Controlled Release Society Newsletter. 2013;30(6):9\u201312.","journal-title":"Controlled Release Society Newsletter"},{"key":"446_CR22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1023\/A:1015880819328","volume":"7","author":"A Supersaxo","year":"1990","unstructured":"Supersaxo A, Hein WR, Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res. 1990;7:167\u20139.","journal-title":"Pharm Res"},{"key":"446_CR23","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1172\/JCI104248","volume":"40","author":"W Hollander","year":"1961","unstructured":"Hollander W, Reilly P, Burrows BA. Lymphatic flow in human subjects as indicated by the disappearance of I-131-labeled albumin from the subcutaneous tissue. J Clin Invest. 1961;40:222\u201333.","journal-title":"J Clin Invest"},{"issue":"3","key":"446_CR24","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/jcph.4","volume":"53","author":"L Zhao","year":"2013","unstructured":"Zhao L, Ji P, Li Z, Roy P, Sahajwalla CG. The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model. J Clin Pharmacol. 2013;53(3):314\u201325. https:\/\/doi.org\/10.1002\/jcph.4.","journal-title":"J Clin Pharmacol"},{"issue":"1s","key":"446_CR25","doi-asserted-by":"publisher","first-page":"130s","DOI":"10.18433\/jpps30028","volume":"21","author":"N Varkhede","year":"2018","unstructured":"Varkhede N, Forrest ML. Understanding the monoclonal antibody disposition after subcutaneous administration using a minimal physiologically based pharmacokinetic model. J Pharm Pharm Sci. 2018;21(1s):130s\u201348s. https:\/\/doi.org\/10.18433\/jpps30028.","journal-title":"J Pharm Pharm Sci"},{"issue":"5","key":"446_CR26","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1080\/19420862.2018.1458808","volume":"10","author":"WF Richter","year":"2018","unstructured":"Richter WF, Christianson GJ, Frances N, Grimm HP, Proetzel G, Roopenian DC. Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice. MAbs. 2018;10(5):803\u201313. https:\/\/doi.org\/10.1080\/19420862.2018.1458808.","journal-title":"MAbs."},{"issue":"4","key":"446_CR27","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1097\/PRS.0000000000001136","volume":"135","author":"Tali Friedman","year":"2015","unstructured":"Friedman T, Coon D, Kanbour-Shakir A, Michaels J, Rubin JP. Defining the lymphatic system of the anterior abdominal wall: an anatomical study. Plast Reconstr Surg. 2015:1027\u201332.","journal-title":"Plastic and Reconstructive Surgery"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-020-00446-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12248-020-00446-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-020-00446-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T23:05:09Z","timestamp":1617404709000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12248-020-00446-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["446"],"URL":"https:\/\/doi.org\/10.1208\/s12248-020-00446-z","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,3]]},"assertion":[{"value":"27 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was performed in accordance with the license to perform experimental animal studies given by the Animal Experiments Inspectorate, Danish Veterinary and Food Administration, Ministry of Environment and Food of Denmark.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}}],"article-number":"63"}}